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Abstract: Pancreatic adenocarcinoma is an aggressive cancer with a greater than 95% mortality rate and short survival after diagnosis. 
Chemotherapeutic resistance hinders successful treatment. This resistance is often associated with mutations in codon 12 of the K-Ras 
gene (K-Ras 12), which is present in over 90% of all pancreatic adenocarcinomas. Codon 12 mutations maintain Ras in a constitutively 
active state leading to continuous cellular proliferation. Our study determined if TRAIL resistance in pancreatic adenocarcinomas 
with K-Ras 12 mutations could be overcome by first sensitizing the cells with Benzyl isothiocyanate (BITC). BITC is a component 
of cruciferous vegetables and a cell cycle inhibitor. BxPC3, MiaPaCa2 and Panc-1 human pancreatic adenocarcinoma cell lines were 
examined for TRAIL resistance. Our studies show BITC induced TRAIL sensitization by dual activation of both the extrinsic and 
intrinsic apoptotic pathways.
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Introduction
Pancreatic cancer is the fourth leading cause of 
cancer-related deaths in the United States.1,2 Pancre-
atic cancer includes exocrine, neuroendocrine, and 
adenocarcinoma forms, with adenocarcinoma being 
the most common and having the least favorable prog-
nosis. There are three predominant treatment options; 
surgery, radiation, and chemotherapy. Pancreatic ade-
nocarcinomas are largely resistant to radiation and 
chemotherapy and often inoperable. The combination 
of late detection and chemotherapeutic resistance in 
pancreatic cancers is responsible for a greater than 
95% mortality rate.1,2
TRAIL (TNF-related apoptosis-inducing ligand) 
is a potential chemotherapeutic agent. TRAIL death 
receptors are highly expressed on the surface of trans-
formed cancer cells but generally absent on most 
normal cells.3 The cytotoxic effects of TRAIL are 
pronounced on cancerous cells and trigger apoptosis, 
but leave most noncancerous tissues unaffected.4–6 
Chemotherapeutic resistance to TRAIL-induced apop-
tosis has been associated with mutations in codon 12 
of the K-Ras gene (K-Ras12).4,5
Over ninety percent of pancreatic adenocarcinomas 
harbor a mutation within codon 12 of the K-Ras 
gene.7,8 Although other mutations, such as p53, p16, 
and SMAD 4 have been reported in pancreatic 
adenocarcinomas, mutations of K-Ras are shown to 
be an initiating factor in the formation of pancreatic 
cancers.8 Ras is a G protein that regulates migration, 
cytoskeletal formation, apoptosis, and cellular prolif-
eration, predominantly through the MAP kinase signal 
transduction pathways.9–11 Ras cycles between an 
inactive GDP-bound state and an active GTP- bound 
state.12–16 Endogenous GTPase activity is responsi-
ble for the inactivation of Ras, thus inhibiting Ras-
mediated signaling.17,18 Mutations within codon 12 of 
K-Ras inhibit this endogenous GTPase activity, thereby 
maintaining Ras in its GTP-bound active state.13 Pre-
vious studies have shown that constitutive activation 
of Ras leads to continuous cellular proliferation.
Benzyl isothiocyanate (BITC) has been shown to 
inhibit cell cycle progression.19 BITC is present in 
cruciferous plants and is a member of the isothiocya-
nate family, which have been found to be protective 
against carcinogenesis.20–22 BITC has recently been 
shown to induce G2/M cell cycle arrest by decreasing 
Cdk1, CyclinB1 and Cdc25B protein levels.19,23,24 In 
high doses, BITC produces the formation of reactive 
oxygen species and can induce cell death.19,24,25
Two major pathways, the extrinsic (death receptor) 
pathway and the intrinsic (mitochondrial) pathway 
mediate apoptosis.3 The extrinsic cell death pathway 
begins with external death receptors on the cell sur-
face. When ligands such as TNF alpha, Fas, or TRAIL 
bind to their specific receptor, intercellular signaling 
results in the cleavage and activation of caspase 8.26,27 
Caspase 8 can then cleave effector caspase 3, inducing 
apoptosis directly.28 In addition, in several cell types, 
caspase 8 can also trigger the activation of the intrinsic 
cell death pathway via cleavage of Bid, a proapoptotic 
protein.29 Truncated Bid (t-Bid) is capable of inter-
acting with other pro-apoptotic proteins leading to 
loss of mitochondrial membrane integrity, which has 
previously been shown to trigger the release of cyto-
chrome C.29,30 Cytochrome C release is associated with 
the activation of caspase 9 and subsequently leads to 
the activation of effector caspase 3.31–34
BxPC3, MiaPaCa2 and Panc-1 cell lines were cho-
sen for the current study because these cell lines rep-
resent the most common mutations found in human 
pancreatic adenocarcinomas (Table 1).35–37 BxPC3 
cells, isolated from human pancreatic adenocarci-
noma, are tumorigenic but are wildtype at codon 12 
of the K-Ras gene. Panc-1 cells, harbor a glycine to 
aspartate amino acid change within codon 12, and 
MiaPaCa2 cells, a glycine to cysteine amino acid 
change. Our results indicate that BITC sensitizes 
chemotherapeutically-resistant human pancreatic ade-
nocarcinoma cells to TRAIL-induced apoptosis via 
the activation of dual apoptotic pathways.
Materials and Methods
Materials
Panc-1 and BxPC3 cells were purchased from ATCC. 
Dr. B. Weissman of the University of North Carolina, 
Chapel Hill School of Medicine kindly provided 
MiaPaCa2 cells. Goat-anti-rabbit (W401B) and goat-
anti-mouse (W402B) HRP-conjugated secondary anti-
bodies were purchased from Promega. The primary 
antibodies used were: rabbit polyclonal anti-XIAP 
(Cell Signaling Cat # 2042), rabbit polyclonal PARP 
(Cell Signaling Cat # 9541S), mouse monoclonal cas-
pase 8 (Cell Signaling Cat # 9746), mouse monoclo-
nal active caspase 9 (Upstate Biotech Cat # 05-572), 
and rabbit polyclonal Bid (Cell Signaling Cat # 2002). 
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Mouse monoclonal pan actin was a kind gift from 
Dr. J. Lessard at Cincinnati Children’s Hospital. Rabbit 
polyclonal active caspase 3 antibody was a kind gift 
from Dr. K. Tomaselli at Idun Pharmaceuticals. For 
apoptotic death quantitation, the Roche Cell Death 
ELISA Assay was used (Roche Cat # 1774425). 
Human recombinant TRAIL was purchased from 
R&D Systems (Cat # 375-TEC). Apoptosis-inducing, 
anti-Fas antibody (clone CH-11) was purchased from 
Millipore. BITC was purchased from Sigma-Aldrich 
(Cat # 252492). Nonmethylated Q-VD-OPh (Cat # 
A0004) was a kind gift from Apoptrol, LLC.
Cell culture
BxPC3, MiaPaCa2, and Panc-1 cells were maintained 
in RPMI 1640 with L-glutamine, supplemented with 
5% heat-inactivated fetal bovine serum and 1% 
antibiotic/antimycotic. Cells were maintained at 5% 
CO2 and 37 °C. All cell lines were maintained at 
1 × 105 cells/ml.
Treatment protocol
For collection of whole cell lysates used in Western 
blot analysis, cells were plated at 2 × 105 cells/ml and 
allowed to attach overnight. TRAIL was solubilized in 
0.1% BSA/water. A stock solution of BITC (100 mM) 
was prepared in DMSO and subsequently diluted in 
fresh medium so that the final concentration of DMSO 
was less than 0.1%. An equal volume of DMSO was 
added for the vehicle controls. Both BITC alone and 
BITC with TRAIL groups were treated with a final 
concentration of 5 µM BITC for 18 hrs. The follow-
ing morning, vehicle and BITC alone groups were 
treated with 5 µl 0.1% BSA, whereas in the TRAIL 
and BITC combined group, TRAIL was added to a 
final concentration of 10 ng/ml TRAIL for 6 hrs. Total 
treatment time with BITC was 24 hrs. Cells were then 
collected for whole cell lysates. In cells treated with 
Q-VD-OPh, cells were preincubated for 30 minutes 
with the pan-caspase inhibitor, prior to beginning the 
experimental treatments. Jurkat human T cells (1 × 106 
cells/ml) were treated with 100 ng/ml of apoptosis-
inducing anti-Fas or 1 µg/ml Actinomycin D for 4 hrs 
as positive controls.
Western blots
Whole cell lysates were collected in CHAPS buffer 
(50 mM PIPES pH 6.5, 2 mM EDTA pH 8.0, 0.1% 
CHAPS) containing protease inhibitor, sonicated, and 
centrifuged at 12,000 rpm for 10 minutes at 4 °C. Pro-
tein concentrations were determined using the Brad-
ford assay.38 Cell lysates were treated with reducing 
sample buffer, and boiled for 5 minutes at 100 °C. 
Proteins were resolved on an SDS polyacrylamide 
gel via electrophoresis.31–34 Separated proteins were 
subsequently transferred onto a PVDF membrane in 
Western transfer buffer overnight at 0.1 A. Proteins 
were visualized using Ponceau S staining and the 
membrane was then blocked at room temperature 
for one hour in PBS blocking buffer (1X PBS, 5% 
(w/v) non-fat dry milk, and 0.05% Tween-20) for 
caspase 3 and 9 and Bid. Blots were blocked in TBS 
blocking buffer (1X TBS, 5% (w/v) non-fat dry milk, 
and 0.10% Tween-20) for XIAP, PARP and caspase 8. 
Blots were probed with antibodies specific for XIAP, 
cleaved PARP, active caspase 8 and 9 at (1:1,000) 
overnight at 4 °C. Actin was incubated at (1:16,000) 
for 40 minutes at room temperature (RT) and active 
caspase 3 at (1:4,000) for 2 hours at RT. Blots were 
then incubated with Pierce SuperSignal® West Pico 
Chemiluminescent Substrate following the manufac-
turer’s recommendations and exposed to X-ray film.
Cell death eLisA
For cell death ELISA analysis, cells were plated at 
1 × 105 cells/ml. Vehicle and TRAIL alone groups were 
treated with a final concentration of 0.2% DMSO. BITC 
and BITC with TRAIL groups were treated for 18 hrs 
at a final concentration of 5 µM BITC. The following 
morning, the vehicle and BITC groups were treated 
with 2 µl 0.1% BSA. Cells treated with TRAIL were 
incubated with a final concentration of 10 ng/ml TRAIL 
for 6 hrs. Total treatment time with BITC was 24 hrs. 
Cells were then collected for analysis with the cell death 
Table 1. K-Ras 12 mutations in Bxpc3, Miapaca2, and 
panc-1 human pancreatic cancer cell Lines. Observed 
nucleotide and amino acid changes within codon 12 of 
K-ras in BxPC3, MiaPaCa2, and Panc-1 cell lines.
cell line K-Ras 12 
nucleotide 
change
Amino acid 
change
Reference
BxPC3 GGT none; Gly (37) 
MiaPaCa2 GGT→TGT Gly→Cys (35)
Panc-1 GGT→GAT Gly→Asp (35)
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ELISA assay following the manufacturer’s protocol. 
Roche Cell Death ELISA Assay was used to detect the 
fold increase in apoptotic cell death.29,30
statistical analysis
Statistical analysis was performed using a one-way 
ANOVA. Results were considered to be statistically 
significant at p  0.05. All experiments were per-
formed independently, a minimum of 3 times.
Results
Resistance to TRAIL-induced apoptosis has previ-
ously been reported in pancreatic cancer cells.32 To 
determine the optimal dosage of TRAIL needed to 
induce apoptosis, we first treated Panc-1 cells with 
increasing doses of 1, 10, and 100 ng/ml TRAIL for 
6 hours (Fig. 1A).6,24 TRAIL-induced apoptosis was 
evaluated using the cell death ELISA assay. A dose 
responsive increase in apoptosis was observed with 
increasing amounts of TRAIL. There was no sig-
nificant increase in apoptosis with 1 ng/ml TRAIL 
compared to the vehicle treated cells. A significant 
1.5 fold increase in apoptotic death was observed 
with 10 ng/ml TRAIL when compared to the vehicle 
alone and the 100 ng/ml TRAIL showed a 1.95 fold 
increase in cell death (P  0.05). Since a significant 
increase in apoptosis was observed at 10 ng/ml TRAIL 
and as there was no significant difference in apoptotic 
death between 10 ng/ml TRAIL or 100 ng/ml TRAIL; 
10 ng/ml TRAIL was chosen for all further studies.
We determined the optimal duration for TRAIL 
treatment. Panc-1 and BxPC3 cells were treated with 
10 ng/ml TRAIL for 6, 15 or 24 hours and apoptosis was 
analyzed using the cell death ELISA assay (Fig. 1B). 
Compared to the vehicle, there was a 7.04-fold increase 
in cell death at 6 hrs in BxPC3 cells, at 15 hrs there was a 
4.53 fold increase in cell death, and at 24 hrs there was 
a 3.76 fold increase in cell death. In Panc-1 cells, at 
6 hrs there was a 2.76 fold increase, at 15 hrs there was 
a 0.96 fold increase in cell death, and at 24 hrs there 
was a 1.05 fold increase in cell death. Higher levels of 
TRAIL-induced apoptosis were observed in wildtype 
K-Ras 12 BxPC3 cells, than in the K-Ras 12 mutant 
Panc-1 cell line. The greatest increase in apoptotic 
death in both cell lines was observed at 6 hours and 
this time point was chosen for all further experiments.
BITC is known to induce cell cycle arrest in human 
pancreatic cancer cells.18,22,24 We analyzed the effect 
of BITC on TRAIL-induced apoptosis in BxPC3, 
MiaPaCa2 and Panc-1 cells by the cell death ELISA 
assay. Cells were treated with vehicle, BITC alone, 
TRAIL alone, or BITC in combination with TRAIL. 
Because BITC is a known cell cycle inhibitor, the 
fold change in apoptosis was normalized to cell num-
ber to accurately reflect the amount of apoptosis. The 
normalized cell death ELISA results indicate that 
BITC alone caused a modest increase in apoptosis 
in BxPC3, MiaPaCa2 and Panc-1 cell lines (Fig. 2). 
BxPC3 and MiaPaCa2 cells were the most sensitive to 
TRAIL-induced apoptosis with a greater than 8-fold 
increase in apoptosis compared to vehicle. Panc-1 
cells were the most resistant to TRAIL with only a 
1.24 fold increase in apoptosis.
BxPC3 cells had a 3.84 fold increase in apopto-
sis upon treatment with BITC alone, an 8.65 fold 
increase was observed with TRAIL alone, and a 
12.39 fold increase was seen when cells were treated 
with BITC combined with TRAIL. MiaPaCa2 cells 
had a 2.08 fold increase in apoptosis upon treatment 
with BITC, a 9.12 fold increase with TRAIL alone, 
and an 11.72 fold increase with BITC combined with 
TRAIL. Panc-1 cells underwent a 1.49 fold increase 
in apoptosis upon treatment with BITC, a 1.82 fold 
increase with TRAIL alone, and a 3.45 fold increase 
with BITC combined with TRAIL compared to 
vehicle. Compared to TRAIL treatment alone, BITC 
combined with TRAIL produced a significant increase 
in apoptotic cell death in all three cell lines examined. 
In addition, treatment of BxPC3, MiaPaCa2, and 
Panc-1 cells with non-methylated Q-VD-OPh, a pan 
caspase inhibitor, prevented apoptosis in all three cell 
lines examined (Fig. 2).31
Western blot analysis was performed to identify 
the apoptotic pathways involved in the BITC and 
TRAIL-induced apoptosis of pancreatic adenocarci-
noma cells. BxPC3, MiaPaCa2 and Panc-1 cells were 
treated with vehicle, BITC, TRAIL, or BITC com-
bined with TRAIL and examined for activation of 
the extrinsic apoptotic cell death pathway (Fig. 3). In 
BxPC3 cells, MiaPaCa2, and Panc-1 cells, vehicle or 
BITC alone did not activate initiator caspase 8. Treat-
ment with TRAIL alone induced the cleavage of the 
inactive proform of caspase 8, indicating the activation 
of caspase 8, although no further increase in caspase 8 
cleavage was observed with the combination of BITC 
and TRAIL in all three cell lines (Fig. 3A).
TrAiL resistance in pancreatic adenocarcinomas
Cancer Growth and Metastasis 2009:2 49
TRAIL dose at 6 hrs
Times course for 10 ng/ml TRAIL treatment
F
o
ld
 c
h
an
g
e 
in
 a
p
o
p
to
si
s
TRAIL concentration
F
o
ld
 c
h
an
g
e 
in
 a
p
o
p
to
si
s 3
A
B
2.5
2
1.5
1
0.5
0
9
8
7
6
5
4
3
2
1
0
6 hrs
Time
15 hrs
BxPC3
Panc-1
24 hrs
Vehicle
Vehicle
1 ng/ml 10 ng/ml 100 ng/ml
*
*
Figure 1. Time and dose response of Panc-1 and BxPC3 cells to TrAiL. A) Panc-1 cells were plated 1 × 105 cells/ml. Cells were treated with vehicle, 1, 10 
and 100 ng/ml TrAiL for 24 hours and the dose response was analyzed by cell death eLisA assay, B) BxPC3 and Panc-1 cells were plated at 1 × 105 
cells/ml. Cells were treated with 10 ng/ml TrAiL for 6, 15 or 24 hours and the optimal time course was analyzed using the cell death eLisA. The results 
are represented by fold increase in apoptosis compared to vehicle. Error bars represent standard deviation. *Denotes significance to p  0.05 when 
compared with control.
X-linked inhibitor of apoptosis protein (XIAP) is a 
prosurvival protein and a direct target of caspase 8.42 
Thus if caspase 8 becomes cleaved (and thus activated), 
caspase 8 will cleave its targets. We examined the 
XIAP protein to infer the extent of caspase 8 activation 
by visualizing the loss of the intact 53 kDa XIAP pro-
tein in BxPC3, MiaPaCa2, and Panc-1 cells (Fig. 3B). 
No detectable XIAP cleavage was observed in BxPC3 
cells treated with BITC alone, TRAIL alone, or BITC 
combined with TRAIL. In Panc-1 cells, addition of 
BITC resulted in the loss of intact XIAP. TRAIL 
alone, however, was unable to induce XIAP cleavage. 
BITC combined with TRAIL led to a reduction in 
intact XIAP compared to the vehicle. In MiaPaCa2 
cells, there was no major cleavage of XIAP with vehi-
cle, BITC, and TRAIL alone. Treatment of TRAIL, 
combined with BITC in MiaPaCa2 cells, did trig-
ger the loss of mature XIAP protein, indicative of 
caspase 8 cleavage. The combined treatment of BITC 
with TRAIL led to a reduction in intact XIAP pro-
tein in MiaPaCa2 and Panc-1 cell lines compared to 
TRAIL alone.
In many cell types, the extrinsic (death receptor) path-
way is known to activate caspase 8 and simultaneously 
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Figure 2. BiTC and TrAiL-induced apoptosis in BxPC3, MiaPaCa2, and Panc-1 cells. Analysis of apoptotic induction in BxPC3, MiaPaCa2, and Panc-1 
cells using the cell death eLisA assay. BxPC3, MiaPaCa2, and Panc-1 cells were plated at 1 × 105 cells/ml. Cells were treated with vehicle, 5 µM BiTC 
24 hrs, and 10 ng/ml TrAiL for 6 hrs or both BiTC and TrAiL. The pan-caspase inhibitor, Q-VD-OPh (QVD) was added at 5 µM for 30 minutes prior to 
treatment where indicated. Cell death eLisA results are represented by fold change in apoptosis compared to the vehicle. error bars represent standard 
deviation. *Denotes significance to p  0.05 when compared with control. #Denotes significance to p  0.05 when comparison was made between TrAiL 
alone and BiTC + TrAiL.
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trigger the activation of the intrinsic (mitochondrial) 
pathway via cleavage of the protein, Bid, resulting 
in truncated Bid (t-Bid).29,30 BxPC3, MiaPaCa2 and 
Panc-1 were cells treated with vehicle, BITC alone, 
TRAIL alone, or BITC combined with TRAIL and 
examined for Bid cleavage (Fig. 3C). The loss of intact 
22 kDa Bid is indicative of t-Bid formation and the 
activation of the intrinsic pathway. Vehicle or BITC 
alone did not induce Bid cleavage in BxPC3 cells. 
TRAIL alone produced a complete loss of the inactive 
proform of Bid as did TRAIL combined with BITC. 
Similar to BxPC3 cells, MiaPaCa2 cells were absent 
of Bid cleavage upon treatment with vehicle or BITC 
alone, however, a substantial loss of intact Bid was 
observed when cells were treated with TRAIL alone 
or BITC combined with TRAIL. In Panc-1 cells, treat-
ment with BITC alone did not reduce intact Bid protein; 
however, a progressive increase in cleavage was seen 
upon treatment with TRAIL alone and a complete 
loss of intact Bid was observed with BITC combined 
with TRAIL.
Truncation, and therefore activation, of Bid has been 
shown to induce the intrinsic cell death pathway.33,35 
We sought to determine whether TRAIL combined 
with BITC activated the intrinsic, mitochondrial cell 
death pathway (Fig. 4). BxPC3, MiaPaCa2 and Panc-1 
cells were examined for the activation of caspase 9, 
the initiator caspase for the intrinsic apoptotic death 
pathway (Fig. 4A). In BxPC3 cells treated with BITC 
alone, no cleavage of caspase 9 was observed. Upon 
treatment with TRAIL alone, there was a decrease of 
the proform and detection of an activated caspase 9 
cleavage product. BITC in combination with TRAIL 
slightly increased the amounts of cleaved active 
caspase 9. In MiaPaCa2 cells, there was no appear-
ance of the cleaved, active caspase 9 fragment upon 
treatment of the vehicle, BITC alone, or TRAIL 
alone. TRAIL combined with BITC resulted a dra-
matic decrease in inactive procaspase 9, however, 
little cleaved caspase 9 could be detected. In Panc-1 
cells, there was no cleavage of caspase 9 with BITC 
alone. TRAIL-induced a decrease in the proform and 
Caspase 8
Proform (57 kDa)
Cleaved (45/43 kD)
MiaPaCa 2 Panc 1 BxPC 3 Jurkat
MiaPaCa 2 Panc 1 BxPC 3 Jurkat
MiaPaca 2 Panc 1 BxPC 3 Jurkat
V B B BT TT BT BT BT −V V +
A
B
C
V B B BT TT BT BT BT −V V +
V B B BT TT BT BT BT −V V +
Pan actin
Bid (22 kDa)
XIAP (53 kDa)
Pan actin
Pan actin
*
Figure 3. Analysis of the extrinsic apoptotic Pathway in human pancreatic cancer cells. Activation of caspase 8 was evaluated in BxPC3, MiaPaCa2 and 
Panc-1 cell lines upon treatment with vehicle (V), 5 µM BiTC for 24 hrs (B), 10 ng/ml TrAiL (T) for 6 hrs or both 5 µM BiTC and 10 ng/ml TrAiL (BT). Total 
treatment time was 24 hours. Whole cell lysates were collected, separated, and analyzed by Western blotting described in the Methods and Materials. 
The blots were probed with antibodies to initiator caspase 8 A), XiAP B), or Bid c) and reprobed with actin to ensure equal loading. Jurkat human T cells 
treated with vehicle (-), anti-Fas antibody (A, B) (+), or hrTrAiL (c) (+) were used as negative and positive controls, respectively.
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an increase in the active cleaved fragment. BITC 
combined with TRAIL produced no further increase 
in cleaved caspase 9.
Because both the extrinsic and intrinsic cell death 
pathways trigger effector caspase cleavage, we eval-
uated the effect of BITC and TRAIL on the major 
effector caspase, caspase 3 (Fig. 4B). In BxPC3 cells, 
vehicle and BITC alone show no significant loss of 
inactive procaspase 3. Treatment with TRAIL pro-
duced the appearance of the cleavage product sug-
gesting activation. TRAIL in combination with 
BITC also produced cleaved caspase 3, similar to 
that of TRAIL alone. MiaPaCa2 cells showed no 
cleavage of procaspase 3 when treated with vehicle 
or BITC alone. TRAIL treatment led to a decrease 
in the proform, however the cleaved form was only 
weakly detected. The combined treatment of BITC 
and TRAIL in MiaPaCa2 cells resulted in the loss 
of procaspase 3, but the cleaved form of caspase 3 
was not detected. In Panc-1 cells, there was little 
difference between vehicle and BITC alone with no 
procaspase 3 cleavage. TRAIL alone triggered the 
cleavage of caspase 3 and this cleavage was further 
increased when Panc-1 cells were treated with BITC 
in combination with TRAIL.
To confirm the activation of caspase 3, we exam-
ined PARP, a direct substrate of activated caspase 3 
(Fig. 4C). In BxPC3 cells, there is no appearance of 
cleaved PARP upon treatment with vehicle or BITC. 
TRAIL treatment alone induced a minor amount of 
MiaPaCa 2
MiaPaCa 2
MiaPaCa 2
Panc 1
Panc 1
Panc 1
BxPC 3
BxPC 3
BxPC 3
Jurkat
Caspase 9
Caspase 3
Proform (47 kDa)
Cleaved (37 kDa)
Cleaved (19 kDa)
Proform (35 kDa)
Jurkat
Jurkat
A
B
C
V V VB B BT T TBT BT BT −
−
+
+V
V V
V FasV
V VB
B
B
B
B BT
T
T
T
T TBT BT
BT
BT
BT
BT
Cleaved
PARP
(89 kDa)
Actin
Actin
Cleaved PARP (89 kDa)
Figure 4. Analysis of the intrinsic apoptotic pathway in human pancreatic cancer cells. Activation of caspase 9 was evaluated in BxPC3, MiaPaCa2 and 
Panc-1 cell lines upon treatment with vehicle (V), 5 µM BiTC for 24 hrs (B), 10 ng/ml TrAiL (T) for 6 hrs or both 5 µM BiTC and 10 ng/ml TrAiL (BT). Total 
treatment time was 24 hours. Whole cell lysates were collected, separated, and analyzed by Western blotting described in the Methods and Materials. The 
blots were probed with antibodies to initiator caspase 9 A), caspase 3 B), or PArP c). Arrows indicated procaspase 9 and the cleaved/active fragment. 
Asterisk (*) indicates an unrelated, crossreactive band. Jurkat human T cells treated with vehicle (-), actinomycin (+) (A, B), or anti-fas (+) (c) were used 
as negative and positive controls, respectively.
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PARP cleavage of PARP. A large increase in PARP 
cleavage was detected upon treatment with BITC 
combined with TRAIL. In MiaPaCa2 cells, PARP 
remained intact with vehicle alone and a small amount 
of the cleaved product was observed in cells treated 
with BITC alone. TRAIL increased the appearance 
of cleaved PARP and TRAIL with BITC led to even 
further PARP cleavage in MiaPaCa2 cells. In Panc-1 
cells, there was no appearance of cleaved PARP upon 
treatment of vehicle or BITC alone. However, upon 
treatment of TRAIL, the appearance of the cleaved 
PARP was observed. TRAIL combined with BITC 
further increased PARP cleavage in Panc-1 cells com-
pared to TRAIL alone.
Discussion
Pancreatic cancer is a one of the leading causes of 
death in the United States and chemotherapeutic 
resistance and high mortality in pancreatic cancer are 
associated with point mutations within codon 12 of 
K-Ras.39,40 K-Ras regulates cellular proliferation in 
most cell types and mutations within codon 12 disrupt 
the normal on-off cycling leading to constitutive 
signaling and proliferation.14 This study determined if 
the cell cycle inhibitor, BITC, could sensitize pancre-
atic adenocarcinoma cell lines with mutated K-Ras to 
TRAIL-induced apoptosis.
The cell death ELISA assay was used to quanti-
tate apoptotic death in the pancreatic adenocarcinoma 
cell lines. We determined that 10 ng/ml TRAIL for 
6 hrs was the optimal treatment to induce apoptosis 
in Panc-1 cells. The time course ELISA showed a 
gradual decline in apoptosis from 6 hrs to 24 hours 
(Fig. 1B). Previous studies in our lab have shown that 
cells in culture can undergo secondary necrosis with 
extended treatment periods with cell death inducers.30 
The cell death ELISA assay can exclude necrotic 
death and specifically measure apoptotic death and 
this is a likely explanation for the decrease in cell 
death that was observed at later time points. BxPC3 
cells were very sensitive to TRAIL-induced apopto-
sis compared to resistant Panc-1 cells. This could be 
attributed to their K-Ras12 status, as BxPC3 cells are 
K-Ras 12 WT and Panc-1 cells are K-Ras 12 mutant.
When the cell death ELISA results were normal-
ized, the data indicated that BITC significantly sen-
sitizes all three human pancreatic cancer cell lines 
to TRAIL-induced apoptosis. K-Ras 12 wild type, 
BxPC3 cells undergo the greatest degree of apop-
tosis, as expected. The K-Ras 12 mutant MiaPaCa2 
cells were moderately sensitive to TRAIL. This sug-
gests that the K-Ras 12 (gly→cys) mutation seen in 
MiaPaCa2 cells may not be dominant for chemo-
therapeutic resistance. Alternatively, there are likely 
to be other potential mutations in these cell lines that 
may also contribute to determining overall resistance. 
Panc-1 cells were resistant to TRAIL-induced apopto-
sis, but could be sensitized to TRAIL when treated in 
combination with BITC. Our results demonstrate that 
BITC combined with TRAIL significantly increases 
apoptosis in these human pancreatic cancer cell lines 
compared to TRAIL alone.
Activation of caspase 8 was observed, as TRAIL 
is reported to signal through the death receptor path-
way.41 Initiator caspase 8 cleavage and activation 
can signal directly and induce apoptosis by cleaving 
effector caspase 3. In all three cell lines, caspase 8 
cleavage did occur upon exposure to TRAIL, but no 
further increase was observed when combined with 
BITC. This may occur as TRAIL may have activated 
the maximal amount of caspase 8 activity and there-
fore BITC was unable to further sensitize the cells.
As a target of caspase 8, XIAP cleavage was exam-
ined.41,42 In all three cell lines examined, BITC alone 
or TRAIL alone moderately reduced intact XIAP. The 
combination of BITC and TRAIL produced moder-
ate cleavage of XIAP in BxPC3, but substantial XIAP 
cleavage in Panc-1 and MiaPaCa2 cells. The intact 
XIAP seen in BxPC3 cells, with the combined treatment 
of BITC with TRAIL, may be due to these cells being 
TRAIL sensitive and therefore full effects were exhib-
ited upon treatment of TRAIL alone. Alternatively, the 
reduction in XIAP may be related to reduced transcrip-
tion due to cell cycle inhibition via BITC.
Bid cleavage was studied as it is a direct target 
of caspase 8 and its truncated form can initiate the 
intrinsic cell death pathway. A near complete loss of 
intact Bid was observed in MiaPaCa2 and BxPC3 
treated with TRAIL. Intact Bid still remained upon 
TRAIL treatment alone in Panc-1 cells. This suggests 
that Panc-1 cells are more resistant to TRAIL-induced 
apoptosis than BxPC3 cells or MiaPaCa2, however, 
the combined treatment of BITC with TRAIL led 
to a complete loss of intact Bid. In Panc-1 cells, 
BITC sensitization to TRAIL-induced apoptosis via 
BID cleavage may be a mechanism to overcome the 
Wicker et al
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resistance to TRAIL, and a potential target for further 
analysis. The resistance seen in Panc-1 cells com-
pared to the other cell lines evaluated may suggest 
that particular K-Ras 12 mutations may be associated 
with different levels of chemotherapeutic resistance 
and this is currently under investigation.
Truncated Bid can lead to the activation of the 
intrinsic cell death pathway and caspase 9.29,30 In 
BxPC3 cells, caspase 9 cleavage was increased upon 
treatment with combined BITC and TRAIL relative 
to TRAIL alone. MiaPaCa2 cells had no increase in 
activated caspase 9 with combined treatment but do 
show a decrease in the caspase 9 proform, suggesting 
some sensitization by BITC. Despite no substantial 
increase in cleaved caspase 9 with combined treat-
ment, the results suggest that MiaPaCa2 cells under-
went increased apoptosis as indicated by the loss of 
procaspase 9 protein and the cell death ELISA assay. 
Panc-1 cells are more resistant to TRAIL-induced 
apoptosis, as suggested by lower levels of activated 
caspase 9 compared to BxPC3 cells.
Both the extrinsic and intrinsic cell death pathway 
lead to the activation of the main effector caspase, 
caspase 3.5,29–31 BxPC3, MiaPaCa2 and Panc-1 cell 
lines all show some activation of caspase 3 with 
TRAIL treatment. MiaPaCa2 cells show the least 
amount of active caspase 3. However, a substantial 
decrease in the caspase 3 proform suggests lim-
ited resistance to TRAIL. All three cell lines show 
increased activation of caspase 3 when treated with 
BITC in combination with TRAIL, compared to 
TRAIL alone. BxPC3 cells show the least amount of 
change between TRAIL alone and the combination 
of BITC and TRAIL. This may be because these cell 
lines are very TRAIL sensitive and its full effect is 
seen with TRAIL alone. Cleavage of PARP supports 
the levels of caspase 3 activation.
In conclusion, our results indicate that BITC 
sensitizes BxPC3, MiaPaCa2, and Panc-1 human 
pancreatic cancer cell lines to TRAIL-induced 
apoptosis via dual apoptotic pathways and the induction 
of several key apoptotic proteins, namely caspases 8, 
9 and 3 as well as there respective substrates XIAP, 
Bid and PARP. BITC has also recently been shown 
to sensitize human pancreatic cancer cells to gamma 
irradiation therapy.43 Furthermore, the inhibition of 
STAT-3 and its signaling pathway in human pancre-
atic cancer cells has been suggested as contributing to 
the inhibition of cell growth and induction of apopto-
sis.44 A recent report indicates that STAT-3 is in the 
mitochondria and plays an important role in maintain-
ing the electron transport chain.45 Therefore, BITC’s 
ability to sensitize cells to apoptosis may lie in the 
ability to significantly dampen mitochondrial elec-
tron transport and alter the prosurvial:proapoptotic 
homeostatic balance and these studies are currently 
under investigation. Our results also indicate that 
Panc-1 cells are more resistant to TRAIL than BxPC3 
and MiaPaCa2 cells, possibly suggesting that certain 
K-Ras 12 mutations lead to increased TRAIL resis-
tance. Our data suggest that BITC may be of value 
for the treatment of chemotherapeutically-resistant 
mutant K-Ras 12 pancreatic adenocarcinomas, as 
BITC sensitizes human pancreatic cancer cells to 
TRAIL-induced apoptosis.
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